Anesthesia and Non-small Cell Lung Cancer Recurrence

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

5384 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-01

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There has been ongoing debate about the relationship between cancer recurrence and anesthetic management. Therefore, the investigators will test the hypothesis that the recurrence free survival (RFS) after curative resection of NSCLC is higher in patient who received total intravenous anesthesia (TIVA) than volatile anesthetics in this multi-center randomized trials.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Combined General/Regional Anesthesia on Cancer Recurrence in Patients Having Lung Cancer Resections

NCT02840227

Non-small Cell Lung Cancer

WITHDRAWN NA

Regional Anesthesia and Lung Cancer Recurrence

NCT01179308

Lung Cancer

TERMINATED NA

Epidural Anesthesia-analgesia and Long-term Survival After Lung Cancer Surgery

NCT02801409

Lung Cancer Thoracic Surgery Anesthesia, Epidural +2 more

COMPLETED NA

Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk

NCT07347977

Non-Small Cell Lung Cancer Recurrence Survival Analysis

NOT_YET_RECRUITING NA

Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in N2 Positive IIIA Non Small Cell Lung Cancer (NSCLC)

NCT00452803

Lung Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Surgery is the primary treatment for non-small cell lung cancer (NSCLC), but microscopic residual disease may be unavoidable. Preclinical studies have shown that volatile anesthetics might suppress host immunity and promote a pro-malignant environment which supports cancer cell proliferation, migration, and angiogenesis, whereas propofol may preserve cell-mediated immunity and inhibits tumor angiogenesis. However, clinical evidence that propofol-based total intravenous anesthesia (TIVA) can reduce tumor recurrence after curative resection remains inconsistent due to retrospective observational nature of previous studies. Therefore, the investigators will test the hypothesis that the recurrence free survival (RFS) after curative resection of NSCLC is higher in patient who received TIVA than volatile anesthetics in this multi-center randomized trials.

This double-blind, randomized trial will enroll patients at 22 international sites, subject to study registration, institutional review board approval, and patient written informed consent. Eligible patients are adult patients undergoing lung resection surgery with curative intent for NSCLC. At each study site, enrolled subjects will be randomly allocated into the TIVA and GAS group with a 1:1 ratio. A centralized, password-protected, and encrypted web-based electronic case report form will be used for randomization and data upload. This pragmatic trial does not standardize any aspect of patient care. However, potential confounders will be balanced between the study arms.

The primary outcome will be recurrence free survival (RFS). Secondary outcomes will be overall survival and complications within postoperative 7 days. Enrollment of 5384 patients will provide 80% power to detect a 3% treatment effect (hazard ratio of 0.83) at alpha 0.05 for RFS at 3 years.

Confirmation of the study hypothesis would demonstrate that a relatively minor and low cost alteration in anesthetic management has the potential to reduce cancer recurrence risk in NSCLC, an ultimately fatal complication. Rejection of the hypothesis would end the ongoing debate about the relationship between cancer recurrence and anesthetic management.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-small Cell Lung Cancer Surgery Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TIVA group

The TIVA group will receive propofol for both induction and maintenance of general anesthesia.

Group Type EXPERIMENTAL

Propofol

Intervention Type DRUG

Propofol will be used for the induction and maintenance of general anesthesia.

GAS group

The GAS group will receive one or more volatile anesthetics (sevoflurane, desflurane, or isoflurane) for induction and maintenance of anesthesia during the surgery. For GAS group, propofol, midazolam, remimazolam, etomidate, or ketamine can be used with inhalation agents as co-induction agents under the discretion of the attending anesthesiologist.

Group Type ACTIVE_COMPARATOR

Inhaled anesthetics

Intervention Type DRUG

Inhaled anesthetics will be used for the maintenance of general anesthesia.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Propofol

Propofol will be used for the induction and maintenance of general anesthesia.

Intervention Type DRUG

Inhaled anesthetics

Inhaled anesthetics will be used for the maintenance of general anesthesia.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Propofol 1% or 2% inj. Sevoflurane, Desflurane, Isoflurane

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* American Society of Anesthesiologists physical status (ASA) Ⅰ-Ⅲ
* The Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Lung resection surgery (segmentectomy, lobectomy, bilobectomy, pneumonectomy; video-assisted, robot-assisted, or open) with curative intent for NSCLC (clinical Tumor, Node, Metastasis (TNM) stage Ⅰ- ⅢA).

Exclusion Criteria

* Distant metastasis or malignant tumor in other organs that according to the attending surgeon is not in long-term remission
* Severe neurologic conditions
* Severe hepatic disease (Child-Pugh classification C)
* Renal failure requiring renal replacement therapy
* History of anesthesia and/or surgery within 1 yr
* Previous surgery due to lung cancer (except diagnostic biopsies)
* Contraindications to any study medication (history of allergy, hypersensitivity reaction, or any other contraindication)
* Planned joint extrapulmonary procedure
* Surgery under cardiopulmonary bypass or extracorporeal membrane oxygenation
* Postoperative sedation
* Pregnancy, or lactation
* Patient refusal.

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No